References
- Chetcuti Zammit S, Koulaouzidis A, Sanders DS, et al. Overview of small bowel angioectasias: clinical presentation and treatment options. Expert Rev Gastroenterol Hepatol. 2018;12(2):125–139. doi: 10.1080/17474124.2018.1390429
- García-Compeán D, Del Cueto-Aguilera ÁN, Jiménez-Rodríguez AR, et al. Diagnostic and therapeutic challenges of gastrointestinal angiodysplasias: a critical review and view points. World J Gastroenterol. 2019;25(21):2549–2564. doi: 10.3748/wjg.v25.i21.2549
- Goltstein LCMJ, Grooteman KV, Rocco A, et al. Effectiveness and predictors of response to somatostatin analogues in patients with gastrointestinal angiodysplasias: a systematic review and individual patient data meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(11):922–932. doi: 10.1016/S2468-1253(21)00262-4
- Gutierrez M, Kesavan C, Das A, et al. Strategic management of bleeding small bowel gastrointestinal angiodysplasias (GIADs): a 12 year retrospective review in a veteran population and cost comparison. Diagnostics (Basel). 2023;13(3):525. doi: 10.3390/DIAGNOSTICS13030525
- Sakai E, Ohata K, Nakajima A, et al. Diagnosis and therapeutic strategies for small bowel vascular lesions. World J Gastroenterol. 2019;25(22):2720–2733. doi: 10.3748/wjg.v25.i22.2720
- Holleran G, Hall B, Hussey M, et al. Small bowel angiodysplasia and novel disease associations: a cohort study. Scand J Gastroenterol. 2013;48(4): doi: 10.3109/00365521.2012.763178
- Ge ZZ, Chen HM, Gao YJ, et al. Efficacy of thalidomide for refractory gastrointestinal bleeding from vascular malformation. Gastroenterology. 2011;141(5):1629–37.e374. doi: 10.1053/j.gastro.2011.07.018
- Rai U, Thrimawithana TR, Valery C, et al. Therapeutic uses of somatostatin and its analogues: Current view and potential applications. Pharmacol Ther. 2015;152:98–110. doi: 10.1016/j.pharmthera.2015.05.007
- Tai FWD, Chetcuti-Zammit S, Sidhu R. Small bowel angioectasia–the clinical and cost impact of different management strategies. Clin Res Hepatol Gastroenterol. 2023;47(8):102193. doi: 10.1016/j.clinre.2023.102193
- Goltstein LCMJ, Grooteman KV, Bernts LHP, et al. Standard of care versus octreotide in Angiodysplasia-related bleeding (the OCEAN study): a multicenter randomized controlled trial. Gastroenterology. 2023 Dec;166(4):690–703. doi: 10.1053/j.gastro.2023.12.020
- Chen H, Shan W, Tang M, et al. Thalidomide for recurrent bleeding due to Small-Intestinal Angiodysplasia. N Engl J Med. 2023;389(18):1649–1659. doi: 10.1056/NEJMoa2303706
- Garrido A, Sayago M, López J, et al. Thalidomide in refractory bleeding due to gastrointestinal angiodysplasias. Rev Esp Enferm Dig. 2012;104(2):69–71. doi: 10.4321/S1130-01082012000200005
- Ghobrial IM, Rajkumar SV. Management of thalidomide toxicity. J Support Oncol. 2003;1(3):194–205.
- Junquera F, Feu F, Papo M, et al. A multicenter, randomized, clinical trial of hormonal therapy in the prevention of rebleeding from gastrointestinal angiodysplasia. Gastroenterology. 2001;121(5):1073–1079. doi: 10.1053/gast.2001.28650
- HALT-IT Trial Collaborators. Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial. Lancet. 2020;395(10241):1927–1936. doi: 10.1016/S0140-6736(20)30848-5
- Albitar HAH, Almodallal Y, Papadakis KA, et al. Intravenous bevacizumab reduces transfusion requirements and endoscopic interventions in patients with gastric antral vascular ectasia and small Bowel Angioectasia. Gastroenterology. 2020;158(4):1162–1163.e4. doi: 10.1053/j.gastro.2019.11.027
- Chetcuti Zammit S, Sidhu R, Sanders D. Refractory anaemia secondary to small bowel angioectasias - comparison between endotherapy alone versus combination with somatostatin analogues. J Gastrointestin Liver Dis. 2017;26(4):369–374. doi: 10.15403/JGLD.2014.1121.264.ZAM
- Klímová K, Padilla-Suárez C, Giménez-Manzorro Á, et al. Octreotide long-active release in the treatment of gastrointestinal bleeding due to vascular malformations: cost-effectiveness study. Rev Esp Enferm Dig. 2015;107(2):79–88. doi: 10.1136/GUTJNL-2015-309861.470